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yocardial Infarction Patient
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o Percutaneous
oronary Intervention
aradise Lost or Paradise Renamed?*
imothy D. Henry, MD, David M. Larson, MD
inneapolis, Minnesota
n the 20 years since the ISIS-2 (Second International
tudy of Infarct Survival) was published, therapy for ST-
egment elevation myocardial infarction (STEMI) has un-
ergone a remarkable evolution (1). The demonstration of
enefit of fibrinolysis versus placebo in the ISIS-2 study, the
referred fibrinolytic agent, and the superiority of primary
ercutaneous coronary intervention (PCI) over fibrinolysis
ere all driven primarily by the results of large, randomized,
ulticenter clinical trials. A clear consensus now exists
See pages 917 and 925
hat primary PCI is the preferred reperfusion strategy for
TEMI patients, if performed in a timely manner (2).
mong remaining controversies in care for patients with
TEMI, 2 stand out: the time after which primary PCI is
o longer preferred (door-to-balloon 90 vs. 120 min, or
ossibly longer), and the ideal reperfusion strategy for the
TEMI patient with an expected delay to PCI. Do the
ata available from randomized clinical trials answer
hese questions?
Facilitated PCI has always been an attractive strategy,
ombining the theoretical advantages of fibrinolytic therapy
nd PCI (3,4). Unfortunately, several meta-analysis/systematic
eviews demonstrated no advantage of facilitated PCI over
rimary PCI, and even possible harm (5–7). Two papers
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.E
From the Minneapolis Heart Institute Foundation at Abbott Northwestern
ospital, Minneapolis, Minnesota.ublished in this issue of JACC: Cardiovascular Interventions
ndicate the conclusion “Facilitated Angioplasty: Paradise
ost” (8) may in fact have been premature.
Both reports represent retrospective analyses from the 2
argest and most influential facilitated PCI trials (9,10). In fact,
he 2 trials provide the strongest evidence against a facilitated
CI strategy. Herrmann et al. (11) performed a retrospective
nalysis of the 2,452 patients randomized in the FINESSE
Facilitated Intervention with Enhanced Reperfusion Speed to
top Events) trial stratified by presentation to a spoke (non-
CI center) or hub site, symptom to randomization time, and
hrombolysis In Myocardial Infarction (TIMI) risk score. As
xpected, overall mortality was directly related to TIMI risk
core. Patients with a TIMI risk score 3, presentation to a
poke hospital, and symptom to randomization time4 h had
significant improvement in the 90-day composite end point
death, ventricular fibrillation after 48 h, cardiogenic shock,
nd congestive heart failure), as well as 1-year survival when
andomized to combination facilitated PCI (half-dose rete-
lase and abciximab). As the authors note, this is exactly the
atient population expected to benefit from facilitated PCI
11). A number of key points are made in the retrospective
nalysis of the 1,667 STEMI patients enrolled in the
SSENT-4 PCI (Assessment of the Safety and Efficacy of a
ew Treatment Strategy for AcuteMyocardial Infarction) trial
12). Few patients actually fit the target population for which
acilitated PCI was designed, and the results of the
SSENT-4 PCI trial are actually more closely related to the
ime to treatment than the treatment strategy. The authors
onclude that “the ASSENT-4 PCI trial should not be taken
s grounds for conclusive rejection of facilitated PCI in all its
ariations as currently practiced or studied in ongoing investi-
ations” (12). Despite the inherent risks of retrospective
nalysis, both papers provide insight into the challenges of trial
esign (in particular, the balance between inclusion/exclusion
riteria and enrollment expectations) and the extrapolation of
linical trial results into clinical practice.
The insightful reanalysis from the authors of these 2
mportant trials combined with the results of 2 recently
ublished prospective randomized clinical trials should refocus
ur attention on a key question: what is the ideal reperfusion
trategy for the STEMI patient with expected delay to PCI?
he CARESS-AMI (Combined Abciximab Reteplase Stent
tudy in Acute Myocardial Infarction) trial was a prospective
ulticenter trial that randomized 600 high-risk STEMI pa-
ients 75 years of age to half-dose reteplase and abciximab
ith immediate transfer for PCI compared with transfer only
or persistent ST-segment elevation or clinical deterioration.
he primary outcome, a composite of death, reinfarction, or
efractory ischemia at 30 days was significantly reduced in the
harmacoinvasive PCI group (4.4%) compared with the stan-
ard care/rescue PCI group (10.7%) (13). The TRANSFER-
MI (Routine Angioplasty and Stenting after Fibrinolysis to
nhance Reperfusion in Acute Myocardial Infarction) trial
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932andomized 1,059 high-risk STEMI patients at non-PCI
enters to full-dose tenecteplase with immediate transfer for
CI versus tenecteplase with transfer for rescue PCI if the
atients had persistent ST-segment elevation, chest pain, or
emodynamic instability (14). The primary end point—a
omposite of death, reinfarction, and recurrent ische-
ia, new or worsening CHF, or cardiogenic shock within 30
ays—was significantly reduced in patients assigned pharma-
oinvasive PCI (11%) compared with patients receiving stan-
ard care/rescue PCI (17%). Thus, both trials were similar in
hat a pharmacoinvasive PCI strategy was superior to the
urrent guideline-recommended strategy of fibrinolysis plus
escue PCI in patients with an expected delay to PCI. Is
harmacoinvasive PCI simply facilitated PCI renamed?
The terminology itself leads to considerable confusion.
hat are the fundamental differences between facilitated
nd pharmacoinvasive PCI? The pharmacologic regimen
as varied, and the ideal regimen remains unclear for
oth. The major differences are the time to PCI and the
rial design. Facilitated PCI trials in general have had
horter time to PCI and have compared the combination
f fibrinolysis and/or IIb/IIIa inhibitors plus immediate
CI to PCI alone. Pharmacoinvasive PCI trials have been
ore likely to randomize patients at non-PCI hospitals
nd have compared the combination of fibrinolysis and/or
Ib/IIIa inhibitors followed by early PCI to fibrinolysis
lone with an ischemia-guided rescue PCI strategy. The
vidence is mounting that a routine invasive strategy after
brinolytic therapy is not only safe and effective but the
referred approach (15). Like the ideal pharmacologic
egimen, the ideal time to PCI post-fibrinolysis remains
nclear.
Herrmann et al. (11) suggest the conclusions of their study
re exploratory and require validation in a prospective, ran-
omized trial. Theoretically, the FINESSE (Facilitated Inter-
ention with Enhanced Reperfusion Speed to Stop Events)
rial itself was well designed to be that trial, but was plagued
nd ultimately halted by slow enrollment. Therefore, the trial
as underpowered to answer the question, especially consid-
ring that 60% of patients were enrolled at PCI centers and not
spoke” hospitals. In both the FINESSE and ASSENT-4
tudies, the patients most likely to benefit from facilitated PCI
patients who present early with expected delays to PCI) were
nder-represented. The design and successful completion of
uch a trial will be extremely challenging. With the focus on
ime to treatment, it has become increasingly difficult to
erform a randomized placebo-controlled STEMI trial in the
.S. “spoke” hospitals at distances from a PCI hospital that
ead to door-to-balloon times 120 min are predominately
mall, rural, or community hospitals frequently without cardi-
logists on site and lacking sophisticated research structures.
he annual number of STEMI patients presenting to these
spoke” hospitals is small, and therefore a large number of
ospitals will be needed. These may be insurmountable issues,specially in the U.S. In the absence of a well-designed clinical
rial, what are our current options for the STEMI patient with
xpected delay to PCI, and how many patients does this
epresent?
It is important to emphasize that patients presenting to
PCI hospital and those with short transfer times should
eceive primary PCI as fast as possible with a goal
oor-to-balloon time of 120 min. The current focus on
ncreasing timely access to PCI makes this an obtainable
oal for the majority of STEMI patients (16,17). Still,
he number of STEMI patients treated with delays 120
in is substantial. In the most recent data from the
merican College of Cardiology/National Cardiovascu-
ar Data Registry, 82% of transferred patients had a
oor-to-balloon time 120 min (18). In the Minneapolis
eart Institute Level 1 regional STEMI network, 34% of
ransferred patients have a door-to-balloon time 120
in, including 52% of patients transferred from hospitals
0 to 210 miles from the PCI center (19). Based on the
INESSE trial investigators criteria of patients present-
ng to a spoke hospital with symptoms to randomization
4 h and TIMI risk score 3, 40% to 50% of transferred
atients in our regional STEMI network would benefit
rom a pharmacoinvasive approach.
Five distinct options available for the STEMI patient
ith expected delay to PCI are listed in Table 1. We
elieve there is sufficient evidence to support immediate
ransfer of STEMI patients to a PCI center and the
enefit of having a standardized approach to STEMI
are, which would eliminate option numbers 1 and 5. The
ARESS-AMI and TRANSFER-AMI trials as well as a
umber of smaller trials indicate the pharmacoinvasive
pproach (early invasive strategy after fibrinolysis) is
uperior to full-dose fibrinolytic with a rescue PCI
trategy (13–15). Therefore, in our opinion, the remain-
ng options are a pharmacoinvasive strategy or primary
CI “no matter how long it takes” or “as fast as possible.”
nfortunately, currently available data do not provide
onclusive evidence, but the results from the FINESSE
rial investigators indicate that in high-risk STEMI
atients who present early to a non-PCI center, the
harmacoinvasive strategy may be preferred. Therefore,
aradise may not be lost, just renamed.
Table 1. Reperfusion Options for the Patients With Expected Delays
1 Full-dose ﬁbrinolytic, admission to the non-PCI hospital with selective transfer
for rescue PCI
2 Full-dose ﬁbrinolytic, routine transfer to PCI hospital with aggressive rescue PCI
3 Facilitated or pharmacoinvasive PCI
4 Primary PCI (no matter how long it takes)
5 Any of the above depending on the PCI facility available and the cardiologist
on callPCI percutaneous coronary intervention.
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